Windlas Biotech Ltd
NSE:WINDLAS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Windlas Biotech Ltd
Net Income (Common)
Windlas Biotech Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Windlas Biotech Ltd
NSE:WINDLAS
|
Net Income (Common)
₹609.9m
|
CAGR 3-Years
17%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
Net Income (Common)
₹24.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Syngene International Ltd
NSE:SYNGENE
|
Net Income (Common)
₹3.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
5%
|
|
|
O
|
Onesource Specialty Pharma Ltd
NSE:ONESOURCE
|
Net Income (Common)
-₹179.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sai Life Sciences Ltd
NSE:SAILIFE
|
Net Income (Common)
₹1.7B
|
CAGR 3-Years
201%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Anthem Biosciences Ltd
NSE:ANTHEM
|
Net Income (Common)
₹4.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Windlas Biotech Ltd
Glance View
Windlas Biotech Ltd. operates as a contract development and manufacturing organization (CDMO). The firm provides a range of contract development and manufacturing organization (CDMO) services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics. Its therapeutic categories, such as, anti-diabetic, cardiovascular, neuropsychiatry and respiratory therapies. The Company’s service capabilities include formulation development, technology scale-up and full-scale commercial manufacturing. The company has capabilities for both solid and liquid pharmaceutical dosage forms. The Company’s market its own manufactured nutraceutical, pharmaceutical and ayurvedic products to serve the semi-urban and rural communities. The company also has a salesforce and distribution network spread across over 14 states. The Company’s manufacturing facilities are located at Dehradun in Uttarakhand.
See Also
What is Windlas Biotech Ltd's Net Income (Common)?
Net Income (Common)
609.9m
INR
Based on the financial report for Mar 31, 2025, Windlas Biotech Ltd's Net Income (Common) amounts to 609.9m INR.
What is Windlas Biotech Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
30%
Over the last year, the Net Income (Common) growth was 5%. The average annual Net Income (Common) growth rates for Windlas Biotech Ltd have been 17% over the past three years , 30% over the past five years .
